Senseonics Holdings, INC DEF 14A proxy statements

Senseonics Holdings, Inc. has issued its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, executive compensation votes, and a proposed increase in authorized shares.

Senseonics Holdings, Inc. is seeking stockholder approval for a reverse stock split ranging from 1-for-10 to 1-for-20 to maintain its NYSE American listing and improve stock marketability.

Senseonics Holdings, Inc. has filed a definitive proxy statement with the SEC.

Senseonics Holdings will hold its annual stockholders meeting virtually on May 21, 2025, to elect directors, approve executive compensation, and ratify the appointment of KPMG LLP as its independent auditor.

Senseonics announced strong early launch indicators for its Eversense 365 CGM system, including record new patient shipments and increased prescriber engagement.

Senseonics Holdings is asking shareholders to approve a reverse stock split in the range of 1-for-25 to 1-for-50 to potentially increase its stock price and maintain its NYSE American listing.

Senseonics Holdings, Inc. will hold its annual stockholder meeting virtually on May 22, 2024, with proposals including the election of directors, executive compensation approval, auditor ratification, and an increase in authorized common stock.

Senseonics Holdings is holding its Annual Meeting of Stockholders on May 22, 2024, to vote on key proposals including the election of directors, executive compensation, auditor ratification, and an increase in authorized common stock.